The treatment failure and clinical efficacy comparison of budesonide metered-dose inhaler and systemic steroid in acute COPD exacerbatio
Phase 4
Recruiting
- Conditions
- COPD with acute moderate to severe exacerbation (according to GOLD guideline 2022)COPD, chronic obstructive pulmonary exacerbation, exacerbation
- Registration Number
- TCTR20220926002
- Lead Sponsor
- Department of Emergency Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
Age at least 18 years old
Diagnosed with COPD by spirometry or clinical symptoms according to GOLD guideline 2022
Presents to emergency department with acute moderate to severe exacerbation according to GOLD guideline 2022
Improves after initial treatment with bronchodilator and 1 dose of intravenous dexamethasone
Eligible for Metered-Dose Inhaler used
Exclusion Criteria
Acute respiratory failure
Hypotension despite sufficient of intravenous fluid and vasopressor
Pneumothorax
Cardiac arrest
Tracheostomy
History of systemic corticosteroid used within 1 month prior
Long-term oxygen therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment failure 30 days Revisit, worsening symptom, respiratory failure
- Secondary Outcome Measures
Name Time Method Admission rate 7 days Percent,Intubation rate 7 days Percent,COPD assessment test (CAT) score At arrival Mean or median,COPD assessment test (CAT) score 7 days Mean or median